LOS ANGELES, Oct. 30 /PRNewswire/ -- Elekta, a pioneer in the field of stereotactic radiosurgery, currently is showcasing the broadest portfolio of stereotactic technology in the industry at the 49th Annual Meeting of The American Society for Therapeutic Radiology and Oncology (ASTRO). Held October 28-November 1 at the Los Angeles Convention Center, ASTRO is the perfect forum for Elekta to showcase its latest products covering the full spectrum of stereotactic systems and solutions for planning, immobilization, treatment and post-processing.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )
“No other vendor has the breadth of solutions that Elekta offers its users,” says Tomas Puusepp, Elekta President and CEO. “We provide innovations through the continuum of care that help fight serious disease and improve quality of life for patients.”
Of the many programs that have acquired or plan to acquire a new linear accelerator within the next few years, the majority are adding radiosurgery capabilities. With its broad portfolio of solutions, Elekta is uniquely positioned to offer cancer programs the solutions they deem best for delivering radiosurgery.
Leksell Gamma Knife(R) Perfexion(TM) offers state-of-the-art radiosurgery with expanded treatment reach
The newest generation Leksell Gamma Knife(R) is Leksell Gamma Knife(R) Perfexion(TM). Leksell Gamma Knife is the only radiation therapy device cleared by the FDA for the treatment of brain metastases. Brain metastases, tumors originating from cancer in other parts of the body, have been increasing in incidence worldwide, and traditional treatments for these tumors often involve a long period of recovery, as well as side effects like nausea, vomiting and hair loss. Stereotactic radiosurgery with Leksell Gamma Knife Perfexion offers dramatic improvements in quality of life for brain metastases patients, with single-session treatments, faster recovery time and virtually no side effects.
For clinicians, Leksell Gamma Knife Perfexion offers absolute protocol reproducibility, allowing access to extensive Leksell Gamma Knife clinical experience from around the world. In addition, it gives virtually unlimited dose sculpting ability for sub-millimeter accuracy in targeting tumors of any shape, and expands treatment reach to a wider range of anatomical structure, enabling clinicians to treat more patients.
The new Leksell GammaPlan(R) PFX(TM) treatment planning software, now running on a PC-based platform, is as sophisticated as the system it controls. Providing enhanced, user-friendly management of Leksell Gamma Knife Perfexion technology, Leksell GammaPlan PFX gives superior dosimetry performance and excellent radiation protection for both the radiosurgery team and their patients.
Elekta Axesse(TM) provides excellence in SRS and SRT
In addition to innovative cranial radiosurgery solutions, Elekta is displaying Elekta Axesse(TM), a comprehensive and integrated full-body solution for performing both stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT). Elekta Axesse combines true three-dimensional image guidance at the time of treatment with highly conformal beam shaping and robotically controlled 6D sub-millimeter patient positioning to deliver fast, efficient and accurate treatment. All treatment processes from planning to delivery are controlled from a single workstation to streamline workflow.
Elekta Synergy(R) is the Multi-Functional IGRT solution
Elekta Synergy(R) with X-ray Volume Imaging (XVI) enables clinicians to visualize internal structures, including soft tissues, in three dimensions at the time of treatment and in the same frame of reference. This innovative feature minimizes geometric uncertainties from organ motion and deformation as well as slight differences in patient set-up. Elekta Synergy inspires clinical confidence to undertake advanced radiation therapy techniques such as Intensity Modulated Arc Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).
Upgrades for even more efficient stereotactic workflow with Elekta Synergy will be displayed at ASTRO. Medical Intelligence, an Elekta company, will display the non-invasive HeadFIX(R) and BodyFIX(R) patient-specific immobilization devices, which are vacuum-activated for highly accurate and reproducible positioning and immobilization. Elekta is showing three new micro multileaf collimators (MLCs), the most versatile technology available for SRS and SRT. All three micro MLCs - the 3mm, the 5mm and the 7mm leaf width - have improved dose shaping abilities for minimal risk to critical organs.
Illustrious history, solid future in stereotaxy
“Elekta’s stereotactic products demonstrate its commitment to technological innovation and advances in stereotaxy,” says Puusepp. Elekta was founded by the late professor Lars Leksell, a pioneer in minimally invasive surgery and inventor of the Leksell Stereotactic System(R) in 1948 and Leksell Gamma Knife in 1968. Since, Elekta has continued to set new standards in accuracy and therapeutic efficacy in both stereotactic radiation therapy and stereotactic radiosurgery.
“As Elekta develops high quality cost-effective solutions, cancer centers around the world are taking a major interest in adding whole-body radiosurgery to their radiation therapy capabilities,” says Puusepp.
About Elekta
Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.
Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.
Elekta’s systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.
With more than 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at www.elekta.com.
CONTACT: Media inquiries, Michelle Lee, PR and Advertising Manager, +1-
770-670-2447, michelle.lee@elekta.com; Global Marketing inquiries, Peter J.
Gaccione, Vice President, Global Marketing, +1-770-670-2380,
peter.gaccione@elekta.com; Investor inquiries, Peter Ejemyr, Group VP
Corporate Communications, +46 733-611-000 (mobile),
peter.ejemyr@elekta.com, all for Elekta Inc.
Web site: http://www.elekta.com/
